Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OUCRU researchers from Indonesia, Nepal, and Vietnam contributed to the newly published WHO research priorities for AMR. These top 40 priorities, developed by the World Health Organization (WHO) with global collaborators, aim to guide research into drug-resistant infections over the next five years, with a special focus on challenges faced by low- and middle-income countries (LMICs).

Chromogenic Agar L1000120 Blue

The Growing Threat of AMR Worldwide

AMR is one of the most pressing global health challenges of our time. As microbes become resistant to existing medicines, treating infections becomes harder, leading to more severe illness and higher death rates. This has significant economic consequences, in terms of health costs and loss of productivity.

The impact of AMR is especially severe in LMICs. Overuse and misuse of antibiotics, combined with poor sanitation and limited infection control, create an environment where resistant microbes thrive. As a result, people in these regions are more vulnerable to drug-resistant infections, and the burden of AMR is felt more deeply, with higher death rates in LMICs.

Assoc. Prof. Raph Hamers contributed to the new WHO research agenda as one of the core team members.

“Despite the growing attention on AMR as a global health issue, major knowledge gaps still slow down an effective response, especially in LMICs. This limits progress in key areas like infection prevention, vaccines, diagnostics, treatments, and antimicrobial stewardship. Addressing these gaps will require collaboration between governments, academia, civil society, and the private sector,” he said.

As the Head of the Clinical Infectious Diseases Research Programme at OUCRU Indonesia, Raph leads several projects at OUCRU Indonesia that are focused on AMR, including ACORNNASPA, and BCB Study.

 

Read the full story on the Oxford University Clinical Research Unit (OUCRU) website. 

Similar stories

New Hospital Networks for Antimicrobial Stewardship in Vietnam

OUCRU Ha Noi and the National Hospital for Tropical Diseases (NHTD), under the guidance of the Department of Health, are collaborating to establish local hospital networks for Antimicrobial Stewardship (AMS) across Vietnam. This initiative, connecting district hospitals with provincial hospitals, leverages existing systems and resources to enhance AMS implementation and strengthen efforts against antimicrobial resistance (AMR).